ES2421538T3 - Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor - Google Patents

Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor

Info

Publication number
ES2421538T3
ES2421538T3 ES04796860T ES04796860T ES2421538T3 ES 2421538 T3 ES2421538 T3 ES 2421538T3 ES 04796860 T ES04796860 T ES 04796860T ES 04796860 T ES04796860 T ES 04796860T ES 2421538 T3 ES2421538 T3 ES 2421538T3
Authority
ES
Spain
Prior art keywords
abdominal pain
pain associated
cholecystokinin
cck
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04796860T
Other languages
English (en)
Spanish (es)
Inventor
Alexey L Margolin
Bhami C Shenoy
Margaret Mcgrath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Cystic Fibrosis Foundation
Original Assignee
Eli Lilly and Co
Cystic Fibrosis Foundation Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co, Cystic Fibrosis Foundation Therapeutics Inc filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2421538T3 publication Critical patent/ES2421538T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4826Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES04796860T 2003-10-29 2004-10-29 Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor Expired - Lifetime ES2421538T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51555203P 2003-10-29 2003-10-29
US52749003P 2003-12-05 2003-12-05
PCT/US2004/036228 WO2005042012A1 (en) 2003-10-29 2004-10-29 Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain

Publications (1)

Publication Number Publication Date
ES2421538T3 true ES2421538T3 (es) 2013-09-03

Family

ID=34556008

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04796860T Expired - Lifetime ES2421538T3 (es) 2003-10-29 2004-10-29 Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor

Country Status (9)

Country Link
US (2) US7459155B2 (https=)
EP (1) EP1682168B1 (https=)
JP (1) JP2007509982A (https=)
KR (1) KR20060127857A (https=)
AU (1) AU2004285558A1 (https=)
CA (1) CA2544156C (https=)
ES (1) ES2421538T3 (https=)
IL (1) IL175210A (https=)
WO (1) WO2005042012A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
DE102006008613A1 (de) * 2006-02-24 2007-08-30 Dade Behring Marburg Gmbh Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung
US20090175842A1 (en) * 2006-07-11 2009-07-09 Chandrakant Laxminarayan Rathi Dietary anti-bacterial compositions
US8246950B2 (en) 2007-02-20 2012-08-21 Aptalis Pharma Limited Stable digestive enzyme compositions
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
UA111726C2 (uk) 2010-10-01 2016-06-10 Апталіс Фарма Лімітед Препарат панкреліпази низької сили з кишковорозчинним покриттям
AU2012253379A1 (en) 2011-05-12 2013-11-21 Healthpoint, Ltd. Wound debridement compositions containing seaprose and methods of wound treatment using same
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
US20130156884A1 (en) * 2011-12-19 2013-06-20 Triarco Industries Protease enzymes for increased protein digestion rate and absorption and methods of using the same
WO2013122979A1 (en) 2012-02-15 2013-08-22 Chirhoclin, Inc. Methods for treating pain associated with chronic pancreatitis
MX2014013745A (es) 2012-05-11 2016-05-05 Smith & Nephew Inc Uso de seaprose para eliminar la pelicula biologica bacteriana.
US11406718B2 (en) 2012-05-29 2022-08-09 Chirhoclin, Inc. Methods of detecting pancreobiliary ductal leaks
MX2016001593A (es) 2013-08-09 2016-09-29 Allergan Pharmaceuticals Int Ltd Composicion de enzima digestiva adecuada para administracion enterica.
RU2016110800A (ru) 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
JP2017519490A (ja) 2014-06-19 2017-07-20 アプタリス ファルマ リミテッド 膵臓抽出物からのウイルス汚染の除去方法
CA3031866A1 (en) 2016-07-27 2018-02-01 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
WO2018140707A1 (en) 2017-01-30 2018-08-02 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce eliminate bacterial biofilms from surfaces
US11744878B2 (en) 2020-08-19 2023-09-05 Chirhoclin, Inc. Methods for treatment of COVID-19 syndrome
US20240315972A1 (en) 2021-07-12 2024-09-26 Zidkiyahu Simenhaus Protein containing bio-active compositions comprising cellulose microparticle carriers

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2129947A1 (en) 1971-03-23 1972-11-03 Amano Pharma Co Ltd Anti-inflammatory protease prepn - from aspergillus
JPS5692217A (en) * 1979-12-26 1981-07-25 Kowa Co Easily absorbable enzyme preparation
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
JPS62215533A (ja) * 1986-03-17 1987-09-22 Shigemi Fujisaki 膠原病又は関節リウマチの予防治療剤
JPS61293927A (ja) * 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
JPH01132533A (ja) * 1987-11-18 1989-05-25 Toa Yakuhin Kogyo Kk 動物用薬剤
JPH01238538A (ja) * 1988-03-18 1989-09-22 Toa Yakuhin Kogyo Kk 健胃消化剤
JPH02292226A (ja) 1989-05-08 1990-12-03 Shigemi Fujisaki 障害された神経細胞賦活予防治療剤
US5514373A (en) 1992-05-22 1996-05-07 Harris, Jr.; Roosevelt D. Topical preparation
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
WO1998036734A1 (en) * 1997-02-21 1998-08-27 Beth Israel Deaconess Medical Center Inc. A novel nutritional therapy which minimizes plasma cholecystokinin (cck) levels
JPH1149699A (ja) 1997-08-01 1999-02-23 Masao Igarashi 女性慢性下腹疼痛症候群治療剤
US6413512B1 (en) 1998-02-13 2002-07-02 National Enzyme Company Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
ATE295737T1 (de) * 2000-11-02 2005-06-15 Cilian Ag Verwendung von aus ciliaten gewonnenen enzymen als verdauungsfördernde arzneimittel
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
US20030026794A1 (en) 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
US6713096B2 (en) 2002-01-04 2004-03-30 Melaleuca, Inc. Dietary supplements and methods for treating pain and inflammation
US20040038874A1 (en) 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain

Also Published As

Publication number Publication date
WO2005042012A1 (en) 2005-05-12
CA2544156A1 (en) 2005-05-12
US7459155B2 (en) 2008-12-02
IL175210A (en) 2014-02-27
US20050158299A1 (en) 2005-07-21
EP1682168B1 (en) 2013-05-01
EP1682168A1 (en) 2006-07-26
KR20060127857A (ko) 2006-12-13
US20090081184A1 (en) 2009-03-26
IL175210A0 (en) 2006-09-05
AU2004285558A1 (en) 2005-05-12
JP2007509982A (ja) 2007-04-19
CA2544156C (en) 2012-07-10

Similar Documents

Publication Publication Date Title
ES2421538T3 (es) Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
BRPI0510817A (pt) protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
ATE507839T1 (de) Kombinationstherapie
DK1412357T3 (da) Beta-aminotetrahydroimidazo-(1,2-a)-pyraziner og tetrahydrotriazolo-(4,3-a)-pyraziner som dipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
HUS1300040I1 (hu) Csonkolt plazmint alkalmazó gyógyszerészeti vitreolízis
NO20071018L (no) Kombinasjonsbehandling ved a anvende fusjonsproteiner omfattende GLP-1
EA201000399A1 (ru) Композиции и способы использования проостровковых пептидов и их аналогов
WO2002058730A3 (en) Compositions for treatment of ocular neovascularization
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
EP1732484A4 (en) OPHTHALMIC IMPLANT FOR THE TREATMENT OF GLAUCOMA
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
EP1804811A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF FLAVIVERS, PESTIVERS AND HEPACIVIRES
EA200800337A1 (ru) Композиция и способ введения офтальмологически активных средств
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
TR200200821T2 (tr) 5-Beta-sapojenin ve pseudosapojenin türevleri ve bunların bunama tedavisinde kullanımı.
NO20072136L (no) Substans som fremmer GH-sekresjon og anvendelse derav
NO20055136D0 (no) Farmasoytisk sammensetning som innbeffatter et immunosuppressivt stoff for bruk ved behandling av hudsykdommer
WO2005107711A3 (en) Method and composition for treating rhinitis
CL2003002293A1 (es) Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.
NO20013493L (no) Anvendelse av neurotrofin samt analoger derav ved behandling av gastrointestinale hypomotilitetslidelser
MX2007001114A (es) Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano.
WO2003031585A3 (en) Transmembrane serine protease 25
EA200501846A1 (ru) Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом